Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Wolf, JC; Zirlik, A; Sourij, H; Bonderman, D; Niessner, A; Auer, J; Huber, K.
GLP-1-RA in a cardio-metabolic continuum
J KARDIOL. 2023; 30(1-2): 30-34.
Web of Science

 

Co-authors Med Uni Graz

Sourij Harald

Zirlik Andreas

Altmetrics:

Abstract:

Since the introduction of the first Glucagon like peptide-1 receptor agonists (GLP-1-RA) more than 15 years ago a lot has happened in this field und there have been new developments with regards to efficacy and safety. Besides the established use for metabolic control, additional effects have been dis-covered, raising the interest for this drug class also in cardiology and other medical disciplines. Currently, national and international guidelines recommend their use, besides SGLT2 inhibitors, in people with diabetes and established cardiovascular disease. The current American Diabetes Association Guideline 2022 now even recommends their use in patients with high cardiovascular risk "regardless of HbA1C ".The goal of this article is to present a current update on mechanisms of action, safety profile and current clinical indications of this very interesting and still relatively new family of agonists on the Glucagon like peptide-1 receptor. J Kardiol 2023; 30 (1-2): 30-4.

Find related publications in this database (Keywords)

GLP-1-RA

Liraglutide

Semaglutide

Dulaglutide

Exenatide

Lixisenatide

ASCVD

diabetes

© Med Uni Graz • Imprint